Table 1.
Participant demographics, PET, and sleep characteristicsa
| Demographics (n = 89) | |
|---|---|
| Age, yr | 78.1 ± 7.6 |
| Female, n (%) | 56 (63) |
| APOE e4 carriers,b n (%) | 23 (27) |
| Education, yr | 17.0 ± 2.0 |
| Mini-Mental State Examination | 28.6 ± 1.4 |
| Body mass index | 25.6 ± 4.2 |
| PET imaging | |
| PiB status, n (%) | PiB+ 45 (51) PiB- 44 (49) |
| FTP Braak staging, n (%) | Braak 0: 16 (18) Braak I/II: 57 (64) Braak III/IV: 16 (18) |
| PiB+ within FTP Braak stage, n (%) | Braak 0: 4 PiB+ (25) Braak I/II: 29 PiB+ (51) Braak III/IV: 12 PiB+ (75) |
| Actigraphy-measured sleep | |
| Nights recorded | 6.8 ± 1.0 |
| Sleep period time, h | 7.9 ± 1.0 |
| Sleep duration, h | 7.2 ± 1.1 |
| Sleep efficiency, % | 90.9 ± 7.8 |
| Fragmentation index | 0.87 ± 0.62 |
| Self-reported sleep | |
| PSQI global score | 4.6 ± 2.9 |
| Sleep duration, h | 7.2 ± 1.1 |
| Sleep efficiency, % | 87.0 ± 9.7 |
aData are mean ± SD. PiB status was determined based on a DVR threshold of 1.065 (Villeneuve et al., 2015). FTP Braak staging, indexing the progression of tau pathology, was assigned to one of four stages based on FTP uptake in Braak-based composite regions, described previously (Maass et al., 2017).
bAPOE genotyping data are not available for 5 subjects.